CXC chemokine ligand 10 (CXCL10) plays a pivotal role in the self-perpetuation of the inflammatory processes in patients with autoimmune thyroid disease. Treatment with methimazole (MMI) reduces serum CXCL10 in patients with Graves' disease. In isolated human thyrocytes, tumor necrosis factor (TNF)a demonstrates a potent synergistic effect on interferon (IFN)g-induced CXCL10 secretion. We investigated the mechanism underlying the synergism between IFNg and TNFa and the effect of MMI on CXCL10 secretion in human thyrocytes. A peroxisome proliferatoractivated receptor g agonist, rosiglitazone (RGZ), a known inhibitor of T helper 1 (Th1)-mediated responses, was also studied for comparison. Experiments were carried out in human thyrocytes isolated from internodular parenchyma of thyroid tissues derived from patients who had undergone surgery for multinodular goiter. ELISA was used to measure CXCL10 levels in culture supernatant. Flow cytometry was used to assess IFNg membrane receptor expression. Specific mRNA analysis was performed by Taqman real-time PCR. Immunofluorescence was performed to detect nuclear translocation of nuclear factor-kB (NF-kB). In human thyrocytes, the synergistic effect of TNFa with IFNg on CXCL10 secretion is due to the upregulation of IFNg receptor expression. MMI decreased cytokine-induced CXCL10 secretion by reducing TNFa-induced upregulation of the IFNg receptor. RGZ decreased the cytokine-induced CXCL10 secretion by impairing NF-kB translocation, without affecting IFNg receptor. MMI and RGZ targeted thyrocytes with the same pharmacological potency, likely acting throughout different mechanisms. Targeting T helper 1-mediated autoimmune thyroid disease with drugs that impair different intracellular pathways could be a novel pharmacological tool.
Introduction
In the pathogenesis of human autoimmune thyroid disorders (AITDs), Hashimoto's thyroiditis and Graves' disease (GD), intrathyroidal lymphocytes seem to play a central role since thyroid antigen recognition is an essential step to T-and/or B-cell stimulation (Weetman & McGregor 1994) . The T-cell pattern involved in GD might change throughout the disease course, with T helper 1 (Th1) as the predominant subtype of CD4 C T cells in patients with recent disease onset and Th2 as the predominant subtype in patients with longer disease duration (Aniszewski et al. 2000) .
In AITDs, a wide range of Th1-associated cytokines, such as interleukin (IL)-1, IL-2, IL-6, interferon (IFN)g, and tumor necrosis factor (TNF)a, are produced. The cytokine production in AITDs has been ascribed to infiltrating T cells, macrophages (Weetman 2003) , thyrocytes (Watson et al. 1995 , Weetman 2004 , and endothelial cells (Romagnani et al. 2002) . The active phase of the disease is characterized by the presence of proinflammatory and Th1-derived cytokines in the thyroid gland, whereas Th2-derived cytokines do not seem to be involved (Wakelkamp et al. 2003) .
Chemokines, a group of low-molecular-weight peptides belonging to the cytokine family, are known to induce the chemotaxis of different leucocyte subtypes (Zlotnik & Yoshie 2000) . The CXC chemokines inducible by IFNg -CXCL9, CXCL10, and CXCL11 -are associated with Th1-mediated immune responses (Antonelli et al. 2006a) . CXCL10, in particular, has been identified as a prototypic chemokine involved in the pathogenesis of glandular autoimmunity (Romagnani et al. 2002 , Rotondi et al. 2003 , Antonelli et al. 2004 , 2005 . Indeed, CXCL10 and its CXCR3 receptor play a pivotal role in the initial phases of AITDs (Romagnani et al. 2002 , Kemp et al. 2003 . In patients with GD, CXCL10 was detected in thyrocytes and endothelial and inflammatory cells, which also expressed peculiarly a large amount of CXCR3 (Garcia-Lopez et al. 2001 , Romagnani et al. 2001 , Aust et al. 2002 , Kemp et al. 2003 , Antonelli et al. 2004 , 2005 .
Furthermore, CXCL10 serum levels were significantly increased in GD patients with recent disease onset (Romagnani et al. 2002) and with active Graves' ophthalmopathy (Antonelli et al. 2006d ) . The CXCL10 secretion was synergistically induced by IFNg and TNFa in isolated thyrocytes in vitro (Garcia-Lopez et al. 2001 , Antonelli et al. 2006d .
Anti-thyroid drugs (ATDs) used in the treatment of hyperthyroidism due to GD, in addition to its effect on thyroperoxidase, inhibited cell-mediated and humoral immune reactions (Volpé 2001 , Laurberg 2006 . While some investigators supported an immunosuppressive effect on immune system cells (Mc Gregor et al. 1980) , other authors favored a direct effect exerted primarily on the thyroid cells, with secondary effects on the immune system via reduced thyrocyte-immunocyte signaling (Volpé 2001 , Laurberg 2006 .
Methimazole (MMI), in particular, has been reported to interfere with immunological signals associated with GD hyperthyroidism (Mc Gregor et al. 1980 , Laurberg 2006 ) and decrease CXCL10 serum levels (Antonelli et al. 2006b,c) . The reduction in circulating CXCL10 levels induced by MMI might suggest that this drug could target thyrocytes as a source of CXCL10.
To our knowledge, the synergistic effect of TNFa on IFNginduced CXCL10 secretion in human thyrocytes has yet to be clarified and it has not been elucidated whether MMI is able to exert any direct effect on these cells. Since we hypothesized that MMI might hamper the cytokine-induced biological pathway(s) leading to CXCL10 secretion, we investigated the mechanisms underlying TNFaCIFNg synergistic effect on CXCL10 secretion in cultured human thyrocytes, and the modulation, if any, by MMI on CXCL10 secretion in the cells stimulated with Th1-type cytokines. We utilized for comparison a peroxisome proliferator-activated receptor g (PPARg) agonist, rosiglitazone (RGZ), a drug for type 2 diabetes treatment, since it has been recently reported to suppress IFNgCTNFa-induced CXCL10 secretion in human thyroid follicular cells of GD patients (Antonelli et al. 2006b,d ) .
Materials and Methods

Chemicals
Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 medium (1:1) with and without phenol red, Ca 2C /Mg 2C -free PBS, BSA fraction V, glutamine, antibiotics, collagenase type IV, NaOH, Bradford reagent, and MMI were from Sigma-Aldrich Corp. The protein measurement kit was obtained from Bio-Rad Laboratories Inc. Fetal bovine serum was purchased from Unipath (Bedford, UK). IFNg, TNFa, and ELISA kit for CXCL10 measurement were from R&D Systems (Minneapolis, MN, USA). Mouse monoclonal anti-thyreoglobulin antibody was from Cell Marque Corporation (Hot Spring, AR, USA). Goat polyclonal anti-Pax8 antibody was from Abcam plc (Cambridge, UK). For flow cytometry analysis, PE-conjugated anti-CD119 (GIR-208, mouse IgG1) mAb was from BD Biosciences (Mountain View, CA, USA), the PE-conjugated anti-TNFR2 (22235.311, mouse IgG2a) mAb was purchased from R&D Systems, and conjugated isotype-matched control Abs were from Southern Biotechnology Associated Inc. (Birmingham, AL, USA; mouse IgG1:clone 15H6, mouse IgG2a:clone HOPC-1). b-Mercaptoethanol was purchased from Fluka Biochemika Ultra (Buchs, Switzerland). For RNA extraction, RNeasy Mini reagent kit was from Quiagen Italy. TaqMan Reverse Transcription Reagents kit, all primer/probe mixes (Taqman Gene Expression Assays), CXCL10 (ID number Hs00171042-m1), IFNgR (ID number Hs00166223-m1), Pax8 (ID number Hs00247586-m1), and 1! Universal Master Mix were from Applied Biosystems (Forster City, CA, USA). Quantitative PCR human reference total RNA was purchased from Stratagene (La Jolla, CA, USA). RGZ was from Glaxo (Welwyn, UK). For immunofluorescence, rabbit polyclonal antihuman primary antibody against nuclear factor-kB (NF-kB) p65 (C-20) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Alexa Fluor 488 goat anti-rabbit conjugate antibody was from Molecular Probes (Eugene, OR, USA). Plasticware for cell cultures and disposable filtration units for growth media preparation were purchased from Corning (Milan, Italy) .
Cell cultures
Primary cultures of thyrocytes were obtained from internodular parenchyma of thyroid tissues derived from 15 patients who underwent surgery for multinodular goiter (10 females: age range 37-83 years and 5 males: age range 32-81 years). Certificates of consent were obtained. Patients did not receive any specific treatment for thyroid disease; thyroid hormones and thyroid autoantibody measurements were in normal range. Thyrocytes were prepared as previously described (Garcia-Lopez et al. 2001 ) with some modifications. Briefly, tissues were minced to fragments as small as possible and treated with 2 mg/ml bacterial collagenase in PBS for 45 min at 37 8C. Digested tissues were mechanically dispersed until a homogeneous suspension was obtained. After washing with PBS, the cell suspension was cultured in DMEM/Ham's F-12 medium (1:1) supplemented with 10% FBS, 2 mmol/l glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin in a fully humidified atmosphere of 95% air-5% CO 2 in plastic 100 mm dishes. Cells began to emerge within 48 h and were used within the fifth-sixth passage. Human thyrocytes expressed paired box (Pax)8, a thyroid-specific transcription factor (Kang et al. 2001) , and were positively stained for thyroglobulin and Pax8 (data not shown).
CXCL10 secretion assay
For CXCL10 secretion assays, 4000 cells were seeded onto 96-well plates in growth medium. After 24 h, the growth medium was removed and cells were washed in PBS and incubated in phenol red-and serum-free medium. After 24 h, different stimuli were added in phenol red-and serum-free medium with 0 . 1% BSA (200 ml/well). Cells in phenol red-and serum-free medium containing 0 . 1% BSA and vehicle (absolute ethanol, 0 . 47%, vol/vol) were used as control. For dose-response assays, cells were incubated for 24 h with TNFa at 0 . 1, 1, 10, 100, and 500 ng/ml or IFNg at 10, 100, 1000, 5000, and 10 000 U/ml, alone or combined with 10 ng/ml of TNFa; or with a combination of IFNg (1000 U/ml)CTNFa (10 ng/ml) in the presence or absence of MMI (1, 2 . 5, 5, 10, 25, 50, 100, 200, 300, 500 , and 1000 ng/ml) or RGZ (0 . 025, 0 . 05, 0 . 1, 0 . 25, 0 . 5, 1, 2 . 5, 5, 10, 20, and 30 mM). The supernatant was harvested and kept frozen at -20 8C until CXCL10 ELISA was performed. Experiments were performed in triplicate or quadruplicate with 4-7 different cell preparations.
CXCL10 ELISA
CXCL10 levels were measured in culture supernatants (diluted 1:20-1:30) using commercially available kits, according to the manufacturer's recommendations. The sensitivity ranged from 0 . 41 to 4 . 46 pg/ml; mean minimum detectable dose was 1 . 67 pg/ml. The intraand inter-assay coefficients of variation were 3 . 1% and 6 . 7% respectively. Samples were assayed in triplicate or quadruplicate. Quality control pools of low, normal, or high concentrations for all parameters were included in each assay. The obtained results, expressed as pg/ml, were normalized by total cell protein amount. Protein extraction was performed on the cell layer in the 96-well plates using 1 M NaOH for 5 min, followed by Bradford reagent for 10-15 min. Protein concentration was measured by spectrophotometric analysis at 595 nm.
Flow cytometry analysis
For cytometry analysis, cells were seeded onto 100 mm dishes in growth medium. Since the cultures were near confluent (about 10 6 ), the growth medium was removed and cells were washed in PBS and incubated in phenol red-and serum-free medium for 24 h. Thereafter, cells were stimulated for 24 h with IFNg (1000 U/ml) or TNFa (10 ng/ml) in phenol red-and serum-free medium with 0 . 1% BSA. Cells in phenol red-and serum-free medium containing 0 . 1% BSA and vehicle (absolute ethanol, 0 . 47%, vol/vol) were used as control. Flow cytometry analysis on cell suspensions was performed as detailed elsewhere (Annunziato et al. 2002) . Briefly, 10 5 cells were incubated with the specific or the isotype control mAb at C4 8C for 30 min; cells were then washed with PBS (pH 7 . 2) containing 0 . 5% BSA and analyzed on a BDLSRII cytofluorimeter using the Diva software (BD Biosciences). Ten thousand events for each sample were acquired. The area of positivity was determined using an isotype-matched mAb. Experiments were performed at least four times with 4-8 different cell preparations.
RNA extraction
For mRNA analysis, cells (500 000 in 60 mm dishes) were maintained in phenol red-and serum-free medium for 24 h. Then, cells were incubated in phenol red-and serum-free medium containing 0 . 1% BSA with different stimuli, according to the following protocol: IFNg (1000 U/ml) or TNFa (10 ng/ml) alone or combined; TNFa (10 ng/ml) combined with MMI (300 ng/ml) or RGZ (5 mM). Cells in phenol red-and serum-free medium containing 0 . 1% BSA and vehicle (absolute ethanol, 0 . 47%, vol/vol) were used as control. Thereafter, cells were trypsinized, washed twice in PBS, and pelleted before lysis. Cell pellet (stored at K80 8C) was resuspended in 350 ml of RLT plus b-mercaptoethanol (10 ml b-mercaptoethanol per ml of RLT buffer). Total RNA from the cells was extracted with the RNeasy Mini reagent kit according to the manufacturer's recommendations. RNA concentration and quality were measured by NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Experiments were performed three/four times with different cell preparations.
Real-time PCR
Total RNA (400 ng) was reverse transcribed using TaqMan Reverse Transcription Reagents kit. Reverse transcription was performed in a final volume of 80 ml containing 500 mM KCl, 0 . 1 mM EDTA, 100 mM Tris-HCl (pH 8 . 3), 5 . 5 mM MgCl 2 , 500 mM of each dNTP, 2 . 5 mM random examers, 0 . 4 U/ml RNase inhibitor, and 1 . 25 U/ml Multiscribe Reverse Transcriptase. The reverse transcription reaction was performed at 25 8C for 10 min, 48 8C for 30 min, and 95 8C for 3 min. Measurement of gene expression was performed by quantitative real-time PCR (TaqMan). The amount of target, normalized to an endogenous reference (18s, pre-developed TaqMan Assay Reagents) and relative to a calibrator (Quantitative PCR human reference total RNA), was given by 2 KDDCt calculation (Livak & Schmittgen 2001) . The formula applied is DDCtZ(Ct target gene KCt 18s )K (Ct target gene calibrator KCt 18s calibrator ). For each sample, 12 . 5 ng of cDNA were added to 10 ml of PCR mix containing each primer/probe mix and 1! Universal Master Mix. The samples were then subjected to 40 cycles of amplification at 95 8C for 15 s and 60 8C for 60 s in the ABI Prism 7700 Sequence Detector (Applied Biosystems).
Immunofluorescence microscopy
Ten thousand cells were seeded onto glass coverslips in growth medium for 24 h and then incubated with serum-free medium overnight, before treatment with TNFa (10 ng/ml) alone or combined with IFNg (1000 U/ml), in the presence or absence of MMI (300 ng/ml) or RGZ (5 mM) for additional 24 h. Cells in phenol red-and serum-free medium containing 0 . 1% BSA and vehicle (absolute ethanol, 0 . 47%, vol/vol) were used as control. For method specificity, slides lacking the primary antibodies or stained with the corresponding nonimmune serum were processed. After washing twice with PBS, cells were fixed with 3 . 7% paraformaldehyde (pH 7 . 4) for 10 min and then permeabilized for 10 min with PBS with 0 . 1% Triton X-100.
Immunostaining was performed as described previously (Vannelli et al. 1995) using primary antibody against NF-kB p65 (1:100), followed by Alexa Fluor 488 conjugate secondary antibody (1:200). The slides were examined with a phase contrast microscope (Nikon Microphot-FX microscope, Nikon, Tokyo, Japan). Experiments were performed thrice with different cell preparations.
Statistical analysis
The statistical analysis was performed using SPSS 12.0 software package (SPSS for Windows 12.0; SPSS Inc. Chicago, IL, USA). The Kolmogorov-Smirnov test was used to test for normal distribution of the data. One-way ANOVA was applied. A P value !0 . 05 was considered significant and was corrected for comparisons using the Dunnett's post hoc test. Data are expressed as meanGS.E.M. The computer program ALLFIT (NIH, Bethesda, MD, USA; De Lean et al. 1978) was used for analysis of sigmoid dose-response curves to obtain estimates of IC 50 of MMI and RGZ.
Results
In human thyrocytes, 24-h treatment with increasing concentration of IFNg (10-10 000 U/ml) significantly increased CXCL10 protein secretion in the supernatant over undetectable basal levels in control cells (P!0 . 01 or P!0 . 05 versus control; Fig. 1A ). This effect was dose dependent and did not achieve plateau (125 . 0G16 . 96 pg/mg protein, mean value at highest dose). Treatment with increasing doses of TNFa (0 . 1-100 and 500 ng/ml) enhanced CXCL10 secretion over control levels as well (P!0 . 01 or P!0 . 05 starting from 10 ng/ml; Fig. 1B ), although the secreted amount of chemokine was low (13 . 49G4 . 49 pg/mg protein, mean value at plateau).
The simultaneous addition of a fixed dose of TNFa (10 ng/ml) to IFNg (10-10 000 U/ml) magnified the IFNginduced CXCL10 secretion until the maximal cell response was evoked (2866 . 35G229 . 43 pg/mg protein, mean value at plateau) at each tested dose (P!0 . 01 or P!0 . 05 versus control and versus IFNg alone corresponding dose), confirming the strong synergistic effect of the combined cytokines (Fig. 1C) . Combination of TNFa (10 ng/ml) and IFNg (1000 U/ml) yielded the highest response, very much in agreement with previous studies (Antonelli et al. 2006d) and, therefore, it was utilized for all subsequent experiments. Taqman real-time PCR analysis confirmed that either IFNg (1000 U/ml) or TNFa (10 ng/ml) similarly upregulated CXCL10-specific mRNA, while cytokine combination resulted in about a 23-fold increase in CXCL10 mRNA, when compared with single cytokine-induced expression (P!0 . 01 or P!0 . 05 versus control, P!0 . 05 versus INFginduced expression; Fig. 1D ).
Cytokines are known to interact through the reciprocal modulation of their receptors. To verify whether the mechanism underlying TNFa and IFNg synergism involved this mechanism in thyrocytes, we performed flow cytometry and mRNA analysis of IFNg and TNFa receptors (IFNgR and TNFaR, type I or II) in thyrocytes stimulated with TNFa (10 ng/ml) or IFNg (1000 U/ml). As shown in Fig versus control) -although the increase in the protein was much higher -whereas IFNg did not exert significant effect on the specific messenger, as shown in Fig. 2B .
To investigate the possible role of MMI in CXCL10 secretion induced by proinflammatory cytokines in human thyrocytes, cells were simultaneously incubated with a combination of IFNg (1000 U/ml) and TNFa (10 ng/ml) and increasing concentrations of MMI (1, 2 . 5, 5, 10, 25, 50, 100, 200, 300, 500 , and 1000 ng/ml) or RGZ (0 . 025, 0 . 05, 0 . 1, 0 . 25, 0 . 5, 1, 2 . 5, 5, 10, 20, and 30 mM) used for comparison. The first two lowest doses of each molecule (1 and 2 . 5 ng/ml for MMI; 0 . 025 and 0 . 05 mM for RGZ) were reported only in ALLFIT interpolation.
The drug concentrations were selected on the basis of their near therapy doses (300 ng/mlZ2 . 63 mM for MMI and 5 mM for RGZ respectively) according to their pharmacokinetics (C max and area under the time-concentration curve, AUC). As shown in Fig. 3A , 24-h cell incubation with MMI decreased, in a dose-dependent manner, cytokine-induced CXCL10 secretion, significantly from 10 ng/ml (P!0 . 01 or P!0 . 05 versus IFNgCTNFa-treated cells).
Similarly, RGZ dose-dependently inhibited CXCL10 secretion significantly (Fig. 3B ) from 1 mM (P!0 . 01 versus
IFNgCTNFa-treated cells).
MMI and RGZ exerted a comparable inhibitory effect on CXCL10 secretion, as confirmed by the simultaneous fitting using ALLFIT program (De Lean et al. 1978) of the inhibitory Fig. 3C . To verify whether the inhibitory effect of both drugs somehow affected the mechanism of synergy between the two cytokines, we analyzed IFNgR expression induced by TNFa (10 ng/ml) in the presence of MMI (300 ng/ml) and RGZ (5 mM) respectively.
Flow cytometry demonstrated that the treatment of thyrocytes with MMI for 24 h significantly reduced IFNgR membrane protein expression induced by TNFa (17 . 4G3 . 8% vs 30G1 . 5% respectively, P!0 . 05), while RGZ did not exert any significant effect (Fig. 4A) . Real-time PCR analysis of specific mRNA confirmed that MMI significantly reduced IFNgR gene expression induced by TNFa (P!0 . 01 versus TNFa-induced expression), although to a lower extent with respect to protein, while RGZ showed no effect (Fig. 4B) .
In order to assess whether MMI or RGZ impaired the pathway of NF-kB, a pleiotropic transcriptional factor tightly associated with several cellular biological functions (Gilmore 2006) and specifically activated by TNFa, we set up a nuclear translocation assay.
Stimulation with TNFa alone (10 ng/ml; Fig. 5B ) or combined with IFNg (1000 U/ml; Fig. 5C ) resulted in the same compact increase (nuclear staining with TNFa: 91 . 42G2 . 13%; nuclear staining with TNFaCIFNg: 89 . 82G2 . 48%) of NF-kB translocation from the cytoplasmic to the nuclear compartment. In Fig. 5A , control cells are depicted, showing 1 . 14G0 . 64% nuclear staining for NFkB. IFNg alone did not exert any effect on NF-kB (data not shown). Since the effect of each drug with TNFa alone or . 1-100 and 500 ng/ml) significantly increased CXCL10 secretion (*P!0 . 05, **P!0 . 01 versus control), although to a low extent (3 . 49G0 . . 49G4 . 49 pg/mg protein, lowest to highest dose).
(C) A fixed dose of TNFa (10 ng/ml) enhanced CXCL10 secretion induced by IFNg (*P!0 . 05, **P!0 . 01 versus control cells, or versus IFNg alone corresponding dose, 8P!0 . 05 versus preceding dose). CXCL10 levels ranged from 1225 . 50G41 . 09 to 2866 . 35G 229 . 43 pg/mg protein, lowest to highest dose. Synergism between the two cytokines effect, initially dose dependent, reached a plateau at the combination of IFNg (1000 U/ml) and TNFa (10 ng/ml). (D) mRNA expression of CXCL10 in thyrocytes treated with IFNg (1000 U/ml) and TNFa (10 ng/ml) alone or combined. CXCL10 mRNA was upregulated by the two single cytokines and it was potentiated by their combination (*P!0 . 05, **P!0 . 01 versus control cells, 8P!0 . 05 versus IFNg-induced expression).
(A-C: ordinate) CXCL10 secretion expressed as pg/mg protein; columns are meanGS.E.M. Data are derived from 4-7 separate experiments using distinct cell preparations (nZ4 and 7). (D: ordinate) CXCL10 mRNA fold increase versus expression in control cells, taken as 1. Data are derived from three separate experiments using distinct cell preparations (nZ3).
combined with IFNg was the same, only the condition with cytokine combination has been reported.
Co-incubation with MMI (300 ng/ml) did not influence nuclear translocation as demonstrated by 83 . 23G3 . 21% of nuclear stain cell positivity (not significant versus cytokinetreated cells; Fig. 5D ). Conversely, simultaneous incubation with RGZ (5 mM) significantly reduced cytokine-stimulated NF-kB translocation, although more than 40% of cell nuclei still showed positivity (nuclear staining 42 . 13G6 . 85%, P!0 . 01 versus cytokine-treated cells; Fig. 5E ). Columns in Fig. 5F summarize the results obtained with all treatments.
Discussion
This study shows that in human thyrocytes the synergistic effect of TNFa with IFNg on CXCL10 secretion is associated with a significant upregulation of IFNgR driven by TNFa, both at protein and gene levels. We, for the first time, provide evidence in thyrocytes that MMI decreases cytokine-induced CXCL10 protein secretion by reducing TNFa-induced upregulation of the IFNg membrane receptor. RGZ similarly decreases cytokine-induced CXCL10 secretion without affecting IFNgR expression. Interestingly, RGZ blocked TNFa-mediated nuclear translocation of NF-kB, pointing out that both drugs abrogated CXCL10 secretion likely by different pathways.
CXCL10 secretion potentiates the Th1 immunity-promoting inflammatory loop, driven by the recruited CD4 C T lymphocytes at inflammation sites, supporting T-cell proliferation and IFNg secretion (Campbell et al. 2004 , Romagnani et al. 2004 . It is well known that TNFa synergizes with IFNg, modulating a number of different biological effects (Krakauer & Oppenheim 1993) . In particular, the synergy between the two cytokines is essential in potentiating inflammatory and Th1 immune responses promoted by IFNg. To date, previous studies reported that CXCL10 secretion is triggered only by IFNg in different resident cell types (Rotondi et al. 2005 , Antonelli et al. 2006d , while in microvascular endothelium TNFa has been reported to upregulate cytokines other than CXCL10 (Sana et al. 2005) .
In our study, TNFa alone elicited a dose-dependent CXCL10 protein secretion in thyrocytes, although to a low extent. Accordingly, TNFa alone was able to upregulate CXCL10 mRNA similarly to IFNg, suggesting that TNFa, in addition to its synergistic effect with IFNg, could contribute to initiating the Th1-mediated response.
Furthermore, the synergic action between the two cytokines in thyrocytes seems to be exerted mainly at a receptor level. A number of cytokines are known to amplify their biological responses both in vivo and in vitro via regulation of the expression of other cytokine receptors (Krakauer & Oppenheim 1993) .
We clearly demonstrated that TNFa upregulated IFNgR at both protein and gene levels, while no significant effect was observed on TNFR type I or II expression (data not shown). Since dose-response curves with IFNg did not reach a plateau, the increase, induced by TNFa, of IFNgR expression may account for the raised magnitude of the response to IFNg, in terms of CXCL10 protein secretion. Accordingly, TNFa was able to potentiate the amount of CXCL10 protein secretion (ng/ml versus pg/ml) dosedependently induced by IFNg, until the maximal cell response was evoked. CXCL10 mRNA specific amount resulted significantly increased in the presence of both cytokines. Since cells with higher number of specific receptors are able to respond to lower concentrations of IFNg, TNFa could be critical in the pathogenesis of AITDs, in line with previous work highlighting the relevance of the TNFa pathway in GD (Diez et al. 2002) .
Our data support the thyroid itself as the main site of CXCL10 secretion perpetuating the Th1-mediated autoimmune cascade in AITDs (Garcia-Lopez et al. 2001 , Romagnani et al. 2002 , Kemp et al. 2003 , Antonelli et al. 2004 . This is very much in agreement with recently published studies in patients showing the reduction of high CXCL10 serum levels in patients with GD after MMI (5, 10, 25, 50, 100, 200, 300, 500 , and 1000 ng/ml) decreased CXCL10 secretion induced by IFNg (1000 U/ml) and TNFa (10 ng/ml; *P!0 . 05, **P!0 . 01 versus IFNgCTNFa- thyrodectomy (Antonelli et al. 2006b ) or after treatment with 131 I (Antonelli et al. 2007) . Treatment with thionamidein AITDs, in addition to its effect on hormone synthesis, is accompanied by a gradual remission of the autoimmune aberration in the majority of patients (Pinchera et al. 1969 , Mc Gregor et al. 1980 , Laurberg 2006 . A recent report describes a reduction in CXCL10 circulating levels in hyperthyroid patients with GD under MMI therapy (Antonelli et al. 2006c) .
We showed that MMI decreased proinflammatory cytokine-induced CXCL10 secretion in thyrocytes in vitro, throughout a strong reduction in TNFa-induced IFNgR membrane protein expression. This effect, matching a reduction in specific amount of IFNgR mRNA, seems to be particularly relevant because it counteracts the magnitude of the CXCL10 secretion in response to IFNg, as previously emphasized. Thus far, it turned out that MMI exerts its immunomodulatory effect on thyrocytes and this should not be surprising since it is well known that it concentrates in follicular cells and not in the surrounding interstitial tissue, where the infiltrating immunocompetent cells are present (Marchant et al. 1972) .
Hyperthyroidism per se plays a minimal role in determining CXCL10 levels that, indeed, are strongly associated with the autoimmune process of the hyperthyroid phase in GD (Romagnani et al. 2002 , Antonelli et al. 2006a ), but not with toxic nodular goiter (Antonelli et al. 2007) . In this light, MMI emerged as a particularly relevant therapy, since it targets the thyroid by dual action, both restoring euthyroidism and decreasing CXCL10 release by thyrocytes.
Concerning drug doses, we want to highlight that the concentrations used in our experiments were selected according to drug plasma or intraglandular concentration range following therapeutic doses, differently from previous in vitro studies that have used far higher drug concentrations than the concentration reached in the thyroid tissue in vivo (Mc Gregor et al. 1980) . Our studies on MMI were performed in comparison to RGZ, a pure PPARg agonist, because it has been recently showed to reduce CXCL10 levels in thyroid follicular cells in GD patients (Antonelli et al. 2006d ) . PPARg agonists are known to play an inhibitory role in the self-perpetuation of chemokine-mediated inflammatory processes in several human cell types (Su et al. 1999 , Marx et al. 2000 , Gosset et al. 2001 , Antonelli et al. 2006d .
RGZ exerted its inhibitory effect on Th1-polarized response in thyrocytes without affecting IFNgR expression. In human thyrocytes, RGZ significantly inhibited CXCL10 secretion at micromolar concentrations by inhibiting NF-kB activation, as demonstrated by the decrease of TNFainduced NF-kB translocation in the cell nucleus. On the contrary, in other cellular models (colon cells transfected with an NF-kB-luciferase reporter element), the mechanism of CXCL10 decrease induced by PPARg agonists seems to be NF-kB independent (Schaefer et al. 2005) . Further studies are necessary to provide details on the RGZ mechanism of action, intended to elucidate the potential effect on Graves' ophthalmopathy. Indeed, while some authors have suggested (Antonelli et al. 2006d ) its beneficial effect, there is experimental and clinical evidence that PPARg agonists may impair the clinical course of Graves' ophthalmopathy by adipogenesis stimulation (Valyasevi et al. 2002 , Starkey et al. 2003 .
In summary, we have demonstrated a novel antiinflammatory effect of MMI that is able to revert Th1 cytokine-mediated CXCL10 secretion directly in thyroid cells by damping the mechanism underlying cytokine synergy. Although further investigations are needed to understand its signaling pathway, MMI targeted thyrocytes with the same pharmacological potency as RGZ, a regulator of the inflammatory response (Campbell 2005) , likely acting through different mechanisms.
Given the pivotal role of IFNg-induced chemokines in Th1-mediated autoimmune thyroid diseases , a combination of different drugs with the same inhibitory effect targeting different intracellular pathways could be a novel pharmacological tool, intended to decrease therapeutic doses and thus minimizing side effects, similar to immunosuppressive protocols for the treatment of other autoimmune diseases or allograft rejection.
